Cargando…

Achieving virological control in pan-resistant HIV-1 infection: A case series

BACKGROUND: HIV-1 pan-resistance refers to a reduced susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and integrase strand tranfer inhibitors. Although still anecdotal, its management remains a concern both for affect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canetti, Diana, Muccini, Camilla, Spagnuolo, Vincenzo, Galli, Laura, Poli, Andrea, Gianotti, Nicola, Feasi, Marcello, Castagna, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897623/ https://www.ncbi.nlm.nih.gov/pubmed/35255457 http://dx.doi.org/10.1016/j.ebiom.2022.103906

Ejemplares similares

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
por: Muccini, Camilla, et al.
Publicado: (2022)

Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV
por: Muccini, Camilla, et al.
Publicado: (2023)

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic
por: Papaioannu Borjesson, Rebecka, et al.
Publicado: (2023)

Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
por: Muccini, Camilla, et al.
Publicado: (2022)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Predictors of lack of serological response to syphilis treatment in HIV-infected subjects
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients
por: Spagnuolo, Vincenzo, et al.
Publicado: (2017)

Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV
por: Spagnuolo, Vincenzo, et al.
Publicado: (2018)

Monkeypox in a patient with undifferentiated connective tissue disease
por: Clemente, Tommaso, et al.
Publicado: (2022)

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
por: Gianotti, Nicola, et al.
Publicado: (2016)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
por: Ripa, Marco, et al.
Publicado: (2021)

Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study
por: Scutari, Rossana, et al.
Publicado: (2021)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load
por: Galizzi, Nadia, et al.
Publicado: (2018)

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study
por: Morsica, Giulia, et al.
Publicado: (2017)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort
por: Nozza, Silvia, et al.
Publicado: (2022)

A history of the Pan American Society for Clinical Virology
por: Hsiung, G.D.
Publicado: (2000)

Guillain-Barré Syndrome with Fatal Outcome during HIV-1-Seroconversion: A Case Report
por: Pontali, Emanuele, et al.
Publicado: (2011)

505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2021)

Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2022)

Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics
por: Candela, Caterina, et al.
Publicado: (2023)

Combination anti‐HIV antibodies to achieve antiretroviral therapy‐free virological suppression in infected individuals
por: Rai, M. Ali, et al.
Publicado: (2022)

Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients
por: Morsica, Giulia, et al.
Publicado: (2022)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
por: Ferretti, Francesca, et al.
Publicado: (2016)

HIV-HBV Coinfection—Current Challenges for Virologic Monitoring
por: Ruta, Simona, et al.
Publicado: (2023)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort
por: Squillace, Nicola, et al.
Publicado: (2016)

Illness Representations of HIV Positive Patients Are Associated with Virologic Success
por: Leone, Daniela, et al.
Publicado: (2016)

Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males
por: Rovelli, Cristina, et al.
Publicado: (2017)

Monkeypox infection among men who have sex with men: PCR testing on seminal fluids
por: Raccagni, Angelo Roberto, et al.
Publicado: (2022)

Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination
por: Raccagni, Angelo Roberto, et al.
Publicado: (2022)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
por: Chereau, Fanny, et al.
Publicado: (2017)

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study
por: Antinori, Andrea, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_el8crsq16b675iqc4l62rcmiqq